Papers matching “intravascular hemolysis” in Complement system in diseases 29
Not finding it? Sign in to also search OpenAlex live.
-
P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
Régis Peffault de Latour, Bing Han, Jaroslaw Pawel Maciejewski, Yutaka Ueda, Rong Fu, Li Zhang, +15 more
3citations -
MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Bing Han, Jaroslaw Pawel Maciejewski, Yasutaka Ueda, Rong Fu, Li Zhang, +15 more
1citations -
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
Antonio Maria Risitano, Alexander Röth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +28 more
2citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Richard Kelly, Austin Gladston Kulasekararaj, Alexander Röth, Phillip Scheinberg, Yasutaka Ueda, +4 more
0citations -
Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Koo Wilson, Sam Williamson, Susanna Libby, Peter Hillmen, David Dingli
0citations -
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target2022 Immunological Reviews review Immunology and Microbiology Complement system in diseases Open access
Antonio Maria Risitano, Camilla Frieri, Eleonora Urciuoli, Luana Marano
52citations -
COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria
Régis Peffault de Latour, Simona Sica, Julia G. Ramos, Jules Hernández‐Sánchez, Jin Seok Kim, Anna Kiialainen, +11 more
3citations -
CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria2020 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Complement system in diseases
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +10 more
1citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations